[Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].
In recent years new antidiabetic medications utilizing incretin effects came to clinical practice, and enthusiasm surrounding this class of drugs has been mounting for their clinical efficacy as well as expected beneficial effects beyond lowering blood glucose levels. New DPP-4 inhibitors are expected to be available soon in addition to currently available DPP-4 inhibitors, sitagliptin, vildagliptin, and alogliptin. GLP-1 analogues, presently liraglutide and exenatide in clinical use, will also see newer alternatives in coming years. Long-acting GLP-1 analogues, which only require weekly or monthly injection, have also been developed, and their favorable clinical results have been reported. In this review, those newly developing DPP-4 inhibitors and GLP-1 analogues and their clinical efficacy are described.